On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) ...

New non-opioid pain killer get FDA approval for acute pain. Patients are taking note. Also demonstrated efficacy, just not ...

On Cloughjordan Community Farm it takes a village to grow 50 sorts of vegetables. The member-owned farm produces high quality ...

The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...

Vertex Pharmaceuticals is expected to outshine projections when it reports Q1 2025 earnings, with strong sales from its ...

Incyte (INCY) delivered earnings and revenue surprises of 14.85% and 4.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?